Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB

Next Previous
Search
Trial Profile

Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Opti-Q

    • Most Recent Events

    • 01 Sep 2022 Results of a secondary analysis assessing factors associated with screening failure and study withdrawal published in the International Journal of Tuberculosis and Lung Disease
    • 16 May 2022 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2022 Planned End Date changed from 1 Feb 2022 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top